Chembio Diagnostics this week said it has received a three-year $2.9 million Small Business Innovative Research Phase II grant from the National Institutes of Health to further develop its protein-based point-of-care tuberculosis test.

The grant, which began March 1, follows on Phase I work in which the company, in collaboration with the Infectious Disease Research Institute, developed a prototype of the test using its Dual Path Platform chromatographic immunoassay technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.